{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:27:03Z","timestamp":1793665623445,"version":"4.5.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40265-022-01782-4","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T10:03:02Z","timestamp":1664964182000},"page":"1481-1488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Varenicline Solution Nasal Spray: A Review in Dry Eye Disease"],"prefix":"10.1007","volume":"82","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"1782_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276\u201383.","journal-title":"Ocul Surf"},{"key":"1782_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438\u2013510.","journal-title":"Ocul Surf"},{"key":"1782_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","volume":"182","author":"KF Farrand","year":"2017","unstructured":"Farrand KF, Fridman M, Stillman IO, et al. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90\u20138.","journal-title":"Am J Ophthalmol"},{"key":"1782_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","volume":"157","author":"AJ Paulsen","year":"2014","unstructured":"Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157:799\u2013806.","journal-title":"Am J Ophthalmol"},{"key":"1782_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/OPTH.S228838","volume":"14","author":"B Shen Lee","year":"2020","unstructured":"Shen Lee B, Kabat AG, Bacharach J, et al. Managing dry eye disease and facilitating realistic patient expectations: a review and appraisal of current therapies. Clin Ophthalmol. 2020;14:119\u201326.","journal-title":"Clin Ophthalmol"},{"key":"1782_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575\u2013628.","journal-title":"Ocul Surf"},{"issue":"1","key":"1782_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ophtha.2018.10.023","volume":"126","author":"EK Akpek","year":"2019","unstructured":"Akpek EK, Amescua G, Farid M, et al. Dry eye syndrome preferred practice pattern\u00ae. Ophthalmology. 2019;126(1):286\u2013334.","journal-title":"Ophthalmology"},{"issue":"2","key":"1782_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/pharmaceutics13020207","volume":"13","author":"P Agarwal","year":"2021","unstructured":"Agarwal P, Craig JP, Rupenthal ID. Formulation considerations for the management of dry eye disease. Pharmaceutics. 2021;13(2):207.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1782_CR9","first-page":"49","volume":"12","author":"V Kumar Raj","year":"2020","unstructured":"Kumar Raj V, Mazumder R, Madhra M. Ocular drug delivery system: challenges and approaches. Int J Appl Pharm. 2020;12(5):49\u201357.","journal-title":"Int J Appl Pharm."},{"key":"1782_CR10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2147\/OPTH.S211611","volume":"13","author":"K Walsh","year":"2019","unstructured":"Walsh K, Jones L. The use of preservatives in dry eye drops. Clin Ophthalmol. 2019;13:1409\u201325.","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"1782_CR11","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.clinthera.2021.07.020","volume":"43","author":"J Nau","year":"2021","unstructured":"Nau J, Wyatt DJ, Rollema H, et al. A phase I, open-label, randomized, 2-way crossover study to evaluate the relative bioavailability of intranasal and oral varenicline. Clin Ther. 2021;43(9):1595\u2013607.","journal-title":"Clin Ther"},{"key":"1782_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.preteyeres.2009.04.003","volume":"28","author":"DA Dartt","year":"2009","unstructured":"Dartt DA. Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases. Prog Retin Eye Res. 2009;28:155\u201377.","journal-title":"Prog Retin Eye Res"},{"key":"1782_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.exer.2003.09.003","volume":"78","author":"ME Stern","year":"2004","unstructured":"Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409\u201316.","journal-title":"Exp Eye Res"},{"issue":"2","key":"1782_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/aos.13844","volume":"97","author":"M Labetoulle","year":"2019","unstructured":"Labetoulle M, Baudouin C, Calonge M, et al. Role of corneal nerves in ocular surface homeostasis and disease. Acta Ophthalmol. 2019;97(2):137\u201345.","journal-title":"Acta Ophthalmol"},{"key":"1782_CR15","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.2147\/OPTH.S284622","volume":"15","author":"MD Yu","year":"2021","unstructured":"Yu MD, Park JK, Kossler AL, et al. Stimulating tear production: spotlight on neurostimulation. Clin Ophthalmol. 2021;15:4219\u201326.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1782_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jtos.2018.11.002","volume":"17","author":"G Dieckmann","year":"2019","unstructured":"Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease: past, present, and future. Ocul Surf. 2019;17(1):20\u20137.","journal-title":"Ocul Surf"},{"issue":"6","key":"1782_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/00003226-199711000-00008","volume":"16","author":"A Gupta","year":"1997","unstructured":"Gupta A, Heigle T, Pflugfelder SC. Nasolacrimal stimulation of aqueous tear production. Cornea. 1997;16(6):645\u20138.","journal-title":"Cornea"},{"key":"1782_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jtos.2022.05.001","volume":"25","author":"SC Pflugfelder","year":"2022","unstructured":"Pflugfelder SC, Cao A, Galor A, et al. Nicotinic acetylcholine receptor stimulation: a new approach for stimulating tear secretion in dry eye disease. Ocul Surf. 2022;25:58\u201364.","journal-title":"Ocul Surf"},{"issue":"3","key":"1782_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/mol.106.025130","volume":"70","author":"KB Mihalak","year":"2006","unstructured":"Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006;70(3):801\u20135.","journal-title":"Mol Pharmacol"},{"key":"1782_CR20","unstructured":"Oyster Point Pharmaceuticals. TYRVAYA\u2122 (varenicline solution) nasal spray: US prescribing information. 2021. https:\/\/www.tyrvaya.com. Accessed 18 Aug 2022."},{"issue":"2","key":"1782_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1124\/jpet.112.194852","volume":"342","author":"T Bordia","year":"2012","unstructured":"Bordia T, Hrachova M, Chin M, et al. Varenicline is a potent partial agonist at \u03b16\u03b22* nicotinic acetylcholine receptors in rat and monkey striatum. J Pharmacol Exp Ther. 2012;342(2):327\u201334.","journal-title":"J Pharmacol Exp Ther"},{"key":"1782_CR22","unstructured":"Pfizer Laboratories Div Pfizer Inc. CHANTIX\u00ae (varenicline tablets, for oral use): US prescribing information. 2019. https:\/\/www.chantix.com. Accessed 18 Aug 2022."},{"issue":"1","key":"1782_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/chemse\/25.1.61","volume":"25","author":"H Alimohammadi","year":"2000","unstructured":"Alimohammadi H, Silver WL. Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat. Chem Senses. 2000;25(1):61\u20136.","journal-title":"Chem Senses"},{"issue":"4","key":"1782_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40123-022-00530-x","volume":"11","author":"GM Dieckmann","year":"2022","unstructured":"Dieckmann GM, Cox SM, Lopez MJ, et al. A single administration of OC-01 (varenicline solution) nasal spray induces short-term alterations in conjunctival goblet cells in patients with dry eye disease. Ophthalmol Ther. 2022;11(4):1551\u201361.","journal-title":"Ophthalmol Ther"},{"key":"1782_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002941","author":"D Wirta","year":"2021","unstructured":"Wirta D, Torkildsen GL, Boehmer B, et al. ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease. Cornea. 2022;41(10):1207\u201316.","journal-title":"Cornea"},{"key":"1782_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.11.004","author":"D Wirta","year":"2021","unstructured":"Wirta D, Vollmer P, Paauw J, et al. Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology. 2022;129(4):379\u201387.","journal-title":"Ophthalmology"},{"key":"1782_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","volume":"24","author":"H Quiroz-Mercado","year":"2022","unstructured":"Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, et al. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study. Ocul Surf. 2022;24:15\u201321.","journal-title":"Ocul Surf"},{"issue":"7","key":"1782_CR28","first-page":"1528","volume":"63","author":"LM Periman","year":"2022","unstructured":"Periman LM, Maiti S, Kabat AG, et al. Bilateral effect of OC-01 nasal spray for treatment of dry eye disease signs and symptoms in subjects with mild, moderate and severe dry eye disease, as determined by baseline eye dryness score [abstract no. A0253]. Investig Ophthalmol Vis Sci. 2022;63(7):1528.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1782_CR29","doi-asserted-by":"publisher","unstructured":"Zitko KL, Ladd L, Dougherty TS. Intranasal varenicline: review of a novel formulation for the treatment of dry eye disease. J Pharm Pract. 2022. https:\/\/doi.org\/10.1177\/08971900221108725.","DOI":"10.1177\/08971900221108725"},{"key":"1782_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108115","volume":"197","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder SC, Stern ME. Biological functions of tear film. Exp Eye Res. 2020;197: 108115.","journal-title":"Exp Eye Res"},{"key":"1782_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2020-000697","volume":"6","author":"M Kim","year":"2021","unstructured":"Kim M, Lee Y, Mehra D, et al. Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol. 2021;6: e000697.","journal-title":"BMJ Open Ophthalmol."},{"issue":"6","key":"1782_CR32","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/jcm10061289","volume":"10","author":"A Kathuria","year":"2021","unstructured":"Kathuria A, Shamloo K, Jhanji V, et al. Categorization of marketed artificial tear formulations based on their ingredients: a rational approach for their use. J Clin Med. 2021;10(6):1289.","journal-title":"J Clin Med"},{"issue":"8","key":"1782_CR33","first-page":"892","volume":"28","author":"DM Visco","year":"2022","unstructured":"Visco DM, Hendrix LH, Sun L, et al. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease. J Manag Care Spec Pharm. 2022;28(8):892\u2013902.","journal-title":"J Manag Care Spec Pharm"},{"key":"1782_CR34","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.22208","author":"DE White","year":"2022","unstructured":"White DE, Hendrix LH, Sun L, et al. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease. J Manag Care Spec Pharm. 2022. https:\/\/doi.org\/10.18553\/jmcp.2022.22208.","journal-title":"J Manag Care Spec Pharm"},{"key":"1782_CR35","first-page":"795","volume":"10","author":"NJ Friedman","year":"2016","unstructured":"Friedman NJ, Butron K, Robledo N, et al. A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease. Clin Ophthalmol. 2016;10:795\u2013804.","journal-title":"Clin Ophthalmol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01782-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01782-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01782-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:08:51Z","timestamp":1744715331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01782-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1782"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01782-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"12 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James E. Frampton is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}